Nektar Therapeutics (NKTR) Q2 2026 Earnings Call: REZPEG Phase III Advances
Source Tradingkey
Key Takeaways
- Nektar Therapeutics ended Q2 2026 with $1.02 billion in cash and investments and no debt. Management said the cash runway extends into Q3 2028, beyond the initial Phase III atopic dermatitis readouts expected in mid-2028.
- Q2 noncash royalty revenue was $10.1 million. Net loss totaled $40.6 million, or $1.23 per basic and diluted share.
- The global ZENITH-AD Phase III program for rezpegaldesleukin, or REZPEG, began randomizing patients in July. The first two studies target biologic- and JAK inhibitor-naive patients, while a treatment-experienced study is scheduled to begin by the end of September 2026.
- Following discussions with the FDA, Nektar finalized a single 850-patient registrational Phase III study for REZPEG in alopecia areata. The company plans to start ZENITH-AA in early 2027 and expects data in the second half of 2029.
- Nektar raised its year-end 2026 cash and investments guidance to $815 million-$840 million. Full-year revenue guidance remains $40 million-$45 million.
- Upcoming clinical catalysts include REZOLVE-AA off-treatment data in Q4 2026, atopic dermatitis off-treatment data in Q1 2027 and initial data from the TrialNet-sponsored type 1 diabetes study in 2027.
Core Financial Data
| Metric | Q2 2026 / Period End | Guidance or Context |
|---|---|---|
| Cash and investments | $1.02 billion | No debt; expected runway into Q3 2028 |
| Public offering proceeds | Approximately $350 million | Net proceeds from April 2026 offering |
| Noncash royalty revenue | $10.1 million | 2026 revenue guidance remains $40 million-$45 million |
| R&D expense | $39.1 million | 2026 guidance of $210 million-$230 million |
| G&A expense | $12.8 million | 2026 guidance of $60 million-$65 million |
| Noncash interest expense | $7.2 million | 2026 guidance of approximately $30 million-$35 million |
| Net loss | $40.6 million | $1.23 per basic and diluted share |
| Year-end cash and investments | — | Raised to $815 million-$840 million |
Business and Operating Performance
REZPEG Phase III program in atopic dermatitis
Disclaimer: The content available on Mitrade Insights is provided for informational and marketing purposes only. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research
Nothing in this material constitutes investment advice, personal recommendation, investment research, an offer, or a solicitation to buy or sell any financial instrument. The content has been prepared without consideration of your individual investment objectives, financial situation, or needs, and should not be treated as such.
Past performance is not a reliable indicator of future performance and/or results. Forward-looking scenarios or forecasts are not a guarantee of future performance. Actual results may differ materially from those anticipated.
Mitrade makes no representation or warranty as to the accuracy or completeness of the information provided and accepts no liability for any loss arising from reliance on such information.
Nothing in this material constitutes investment advice, personal recommendation, investment research, an offer, or a solicitation to buy or sell any financial instrument. The content has been prepared without consideration of your individual investment objectives, financial situation, or needs, and should not be treated as such.
Past performance is not a reliable indicator of future performance and/or results. Forward-looking scenarios or forecasts are not a guarantee of future performance. Actual results may differ materially from those anticipated.
Mitrade makes no representation or warranty as to the accuracy or completeness of the information provided and accepts no liability for any loss arising from reliance on such information.
Recommended Articles
Pi Network Price Annual Forecast: PI set for rocky 2026 as community eyes real-world utilityPi Network (PI) crashed by over 90% in 2025 from its all-time high of $3.00, with minor recovery along the way. The downfall was fueled by low investor confidence as mainnet migrations increased token deposits on Know Your Business (KYB) verified exchanges.
Pi Network (PI) crashed by over 90% in 2025 from its all-time high of $3.00, with minor recovery along the way. The downfall was fueled by low investor confidence as mainnet migrations increased token deposits on Know Your Business (KYB) verified exchanges.
Financial Markets 2026: Volatility Catalysts in Gold, Silver, Oil, and Blue-Chip Stocks—A CFD Trader's OutlookThe financial world is perpetually in motion, but the landscape for 2026 seems to be shaping up to be particularly dynamic. For CFD traders navigating global markets, this heightened volatility could present a distinctive set of challenges and opportunities.
The financial world is perpetually in motion, but the landscape for 2026 seems to be shaping up to be particularly dynamic. For CFD traders navigating global markets, this heightened volatility could present a distinctive set of challenges and opportunities.
Bitcoin steadies at $70k while Ethereum and XRP face key resistance levels; technicals show bearish MACD crossovers despite oversold RSI conditions.
Japan's Nikkei closes at record high as tech earnings overshadow Mideast concernsBy Rocky Swift TOKYO, April 24 (Reuters) - Japan's Nikkei set a closing record high on Friday, capping a third consecutive weekly gain, as enthusiasm over technology sector earnings offset uncertainty over a potential peace deal in the Middle East.The benchmark Nikkei 225 Index .N225 rose 0.9...
By Rocky Swift TOKYO, April 24 (Reuters) - Japan's Nikkei set a closing record high on Friday, capping a third consecutive weekly gain, as enthusiasm over technology sector earnings offset uncertainty over a potential peace deal in the Middle East.The benchmark Nikkei 225 Index .N225 rose 0.9...
Understand how the Strait of Hormuz shock moved markets, and what CFD traders watched next.
